Search Follow us

Pacific Edge (PEB)

Business description

Pacific Edge develops and sells a portfolio of molecular diagnostic tests based on biomarkers for the early detection and management of cancer. Tests utilising its Cxbladder technology for detecting and monitoring bladder cancer are sold in the US, New Zealand and Australia.

On the edge of glory

Initiation | Pharmaceutical & healthcare | 29/09/2014

Pacific Edge (PEB) launched Cxbladderdetect, the first of its portfolio of urothelial cancer diagnostic tests, into the key US market in mid-2013. Sales from paying customers are beginning to feed through following the conclusion of initial user programmes and negotiations are fully underway with key public health organisations. We expect meaningful sales from Cxbladderdetect in calendar 2015 and positive cash flow for the company in calendar 2016. We value Pacific Edge at NZ$1.16 per share.

Edison's research is freely available. We will never ask for your credit card details and you do not need to register. By downloading this research you are agreeing to our terms and conditions, which you can read in full here.

Stock data

Market cap.NZ$104.9m
Last closeNZ$0.230
High / Low (52 weeks)NZ$0.5 / NZ$0.2
Stock market listingNZ
Forecast net debt (NZ$m)0.3
Forecast gearing ratio (%)189
SectorPharmaceutical & healthcare

Price performance

Relative *(30.4)(43.7)(59.6)

* % Relative to local index

Company news